Remdesivir

COVID-19: Nigerian Govt Finally Receives Donation From Trump

Gilead Science Donates 1.5m Vials Of COVID-19 Drug To U.S

May 2, 2020 6:40 am

Gilead Science Inc, maker of the coronavirus drug Remdesivir said it will be donating 1.5 million vials of the drug to help patients in U.S.hospitals.

Chief Executive of the company Daniel O’Day made the pledge during a meeting with President Donald Trump on Friday.

The meeting came after the drug was granted emergency use authorization by the U.S. Food and Drug Administration for COVID-19.

The FDA approval cleared the way for broader use of the drug in more hospitals around the United States.

Read Also: Bill Gates Reveals New RNA Vaccine With ‘Code’

But the authorization applies to patients hospitalized …

This Nigerian Doctor In USA Is Leading Major Study On Remdesivir COVID-19 Drug

Nigerian Doctor In USA Leads Major Study On COVID-19 Drug

May 1, 2020 5:52 am

A bright doctor from the West African country of Nigeria Babafemi Taiwo is leading part of a major study on antiviral drug Remdesivir appearing to treat COVID-19, the potentially deadly respiratory disease caused by the coronavirus, which has killed more than 200,000 people around the world.

CNN interviewed Dr. Taiwo, whose name suggests he is a twin from the southwestern part of Nigeria, to discuss the promising results. Remdesivir, the antiviral drug made by Gilead Sciences, appears to help coronavirus patients recover more quickly than no treatment at all, but it does not significantly reduce death, according to preliminary data …

Remdesivir: COVID-19 Drug Helping Patients Recover Faster

April 30, 2020 6:05 pm

Remdesivir has been shown to speed up recovery times for patients with COVID-19 in a major US-led trial, becoming the first drug with proven benefit against the disease.

Here is what you need to know.

– What is remdesivir? –

Remdesivir is an experimental, broad spectrum antiviral made by US pharmaceutical Gilead Sciences that was first developed to treat Ebola, a viral hemorrhagic fever.

It showed early promise in a primate study in 2016 and was later rolled out for a major trial in the Democratic Republic of Congo, where it was compared against three other medicines.

That study concluded …